Based in Tel Aviv, Israel, Alcobra Pharmaceuticals (ADHD) scheduled a $25 million IPO with a market capitalization of $133 million at a price range mid-point of $11, for Wednesday, May 22, 2013.Five other new IPOs are scheduled for IPOs ...
Based in Tel Aviv, Israel, Alcobra Pharmaceuticals (ADHD) scheduled a $25 million IPO with a market capitalization of $133 million at a price range mid-point of $11, for Wednesday, May 22, 2013.Five other new IPOs are scheduled for IPOs for this week. The full IPO calendar is here.
F-1A filed May 2, 2013
Manager, Joint Managers: Aegis CapitalCo Managers: Sunrise Securities
SUMMARY ADHD is a biopharmaceutical company with a lead product targeted towards Attention Deficit Hyperactivity Disorder, or ADHD. ADHD has completed a Phase 2 study, but TEVA backed out of a collaboration agreement in November 2011 by not making a payment.VALUATION
Valuation Ratios
IPO Mrkt
Price /
Price /
Price /
Price /
% offered
annualizing March qtr
Cap (MM)
Sales
Earnings
BkValue
TangibleBV
in IPO
Alcobra Pharmaceuticals (ADHD)
$113
n/a
-27.6
5.1
5.0
22%
Glossary
ADHD has no revenue, 5